Literature DB >> 18752535

Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care.

J M Teitel1, M Carcao, D Lillicrap, K Mulder, G E Rivard, J St-Louis, F Smith, I Walker, N Zourikian.   

Abstract

All but essential surgery is generally avoided in haemophilia patients with inhibitor antibodies, because of concern about the reliability with which haemostasis can be achieved and maintained in such patients. Orthopaedic surgical procedures which are not required to preserve life fall under this category. As a result, patients with inhibitors may be denied operations, which could greatly enhance their quality of life, and which are routinely offered to other haemophilia patients. While caution is appropriate in recommending surgery in any circumstance, we believe that the threshold for offering validated surgical procedures to patients with inhibitors should be re-evaluated in the light of current surgical and rehabilitative techniques, and the long experience with safe and effective factor VIII inhibitor bypassing agents, namely activated prothrombin complex concentrates and recombinant activated factor FVII. In this article, we review the haematological, surgical and rehabilitative considerations relevant to orthopaedic surgery in haemophilia patients with inhibitors, and provide recommendations for carrying out such procedures.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752535     DOI: 10.1111/j.1365-2516.2008.01840.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  9 in total

Review 1.  Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentrates.

Authors:  Antonio Coppola; Annarita Tagliaferri; Gabriele Calizzani; Fabio Candura; Massimo Franchini; Carlo Ruosi; Giuliano Grazzini; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

2.  Sequential bypassing agents during major orthopedic surgery: a new approach to hemostasis.

Authors:  Craig D Seaman; Margaret V Ragni
Journal:  Blood Adv       Date:  2017-07-18

3.  Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.

Authors:  Y Dargaud; A Pavlova; S Lacroix-Desmazes; K Fischer; M Soucie; S Claeyssens; D W Scott; R d'Oiron; G Lavigne-Lissalde; G Kenet; C Escuriola Ettingshausen; A Borel-Derlon; T Lambert; G Pasta; C Négrier
Journal:  Haemophilia       Date:  2016-01       Impact factor: 4.287

Review 4.  The role of recombinant activated factor VII in the haematological management of elective orthopaedic surgery in haemophilia A patients with inhibitors.

Authors:  Giancarlo Castaman
Journal:  Blood Transfus       Date:  2017-05-16       Impact factor: 3.443

5.  Recombinant factor VIII in the management of hemophilia A: current use and future promise.

Authors:  Jerry S Powell
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

6.  Haemophilia at various stages of life: design of new therapeutic strategies through an interactive course--the Kogeniale project.

Authors:  Elena Santagostino; Maria Messina; Annarita Tagliaferri; Alfonso Iorio; Massimo Morfini
Journal:  Blood Transfus       Date:  2013-01-23       Impact factor: 3.443

7.  PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.

Authors:  Miguel Escobar; James Luck; Yevhenii Averianov; Jonathan Ducore; Maria Fernanda López Fernández; Adam Giermasz; Daniel P Hart; Janna Journeycake; Craig Kessler; Cindy Leissinger; Johnny Mahlangu; Laura Villarreal Martinez; Wolfgang Miesbach; Ismail Haroon Mitha; Doris Quon; Mark T Reding; Jean-François Schved; Oleksandra Stasyshyn; Kateryna V Vilchevska; Michael Wang; Jerzy Windyga; W Allan Alexander; Ahmad Al-Sabbagh; Daniel Bonzo; Ian S Mitchell; Thomas A Wilkinson; Cédric Hermans
Journal:  Haemophilia       Date:  2021-10-06       Impact factor: 4.263

8.  The efficacy of bypassing agents in surgery of hemophilia patients with inhibitors.

Authors:  Hee Young Ju; Hye Lim Jang; Young Shil Park
Journal:  Blood Res       Date:  2015-09-22

9.  Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain.

Authors:  María Mareque; María Eva Mingot-Castellano; María Fernanda López-Fernández; María Teresa Álvarez-Román; Itziar Oyagüez
Journal:  Eur J Haematol       Date:  2020-04-16       Impact factor: 2.997

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.